Owlstone Medical is the global leader in Breath Biopsy for applications in early disease detection. It has presented new data for development of a screening test that help in early detection of lung cancer. Lung cancer is one of the most common forms of cancers in the world. Continuous studies and research works are being carried on all around the world. The results of this trial were presented in two posters at the annual meeting of the European Association for Cancer Research held in Torino, Italy.
The first poster describes Owlstone’s efforts for establishing D5-ethyl-ß-glucuronide as a non-invasive EVOC® Probe for the purpose of early detection of lung cancer. Also, Owlstone determined presence of extracellular ß-glucuronidase in tissue samples from human lung cancers on addition to the ability to detect D5-ethanol in human breath samples through ‘breath biopsy’ after EVOC probe. The results have demonstrated proof of mechanism via successful measurement of D5-Ethanol levels in Breath samples of the patients. The in-human studies are underway with Phase 1a safety assessment and phase 1b dose optimization study almost complete.
The second poster describes a complementary EVOC probe approach for early lung cancer detection based on aldo-keto reductase (AKR) activity. The study was done in vitro on human lung cancer cells and it evaluated the expression of AKRs and the ability to measure AKR-associated Volatile reporters from lung cancer cells. Billy Boyle, co-founder and CEO at Owlstone Medical said, “Through the studies presented, we are now confident we have the evidence we need to proceed to Phase 2 of the EVOLUTION study.”
You can view the presented posters here: “Proof-of-mechanism study for a diagnostic probe compound generating D5-ethanol as an on-breath reporter molecule for lung cancer – Evolution phase 1” and “Using exogenous volatile organic compound (EVOC) probes to target tumour-associated aldo-keto reductase activity: a potential tool to detect lung cancer”.
The information shared in this blog is exclusively for educational purposes and is certainly not an alternative to medical advice.
Subscribe to our newsletter or follow us on Facebook or Twitter today and never miss out an update!